---
title: "CONMED Corp 1Q 2026: Revenue $317M, EPS $0.45— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284788387.md"
description: "CONMED Corp reported Q1 2026 revenue of $317M, a slight decrease from $321.3M in Q1 2025. Net income rose to $13.8M, up 129% year-over-year, with diluted EPS increasing to $0.45, a 137% rise. Orthopedic sales grew 6.8%, offsetting declines from the exit of gastroenterology product lines. Recurring single-use products accounted for 85% of revenue, contributing to improved gross margins, which expanded by 260 basis points. The company continues to optimize its supply chain following the strategic exit from gastroenterology."
datetime: "2026-04-30T14:01:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284788387.md)
  - [en](https://longbridge.com/en/news/284788387.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284788387.md)
---

# CONMED Corp 1Q 2026: Revenue $317M, EPS $0.45— 10-Q Summary

CONMED Corp reported first-quarter 2026 results with revenue of $317M, down slightly from $321.3M a year earlier, while net income rose to $13.8M and diluted EPS increased to $0.45, reflecting improved margins and the impact of a strategic exit from gastroenterology product lines.

**Financial Highlights**

-   Revenue was $317.0M for Q1 2026, compared with $321.3M in Q1 2025; YoY change (1.3%).
-   Net income was $13.8M for Q1 2026, compared with $6.0M in Q1 2025; YoY change 129%.
-   Diluted EPS was $0.45 for Q1 2026, compared with $0.19 in Q1 2025; YoY change 137%.

**Business Highlights**

-   Orthopedic sales grew about 6.8% year over year, driven by procedure-specific products and BioBrace®, helping offset declines from the gastroenterology exit.
-   The company sold gastroenterology-related assets and exited those product lines in Q1 2026, which reduced general surgery sales and contributed to the slight overall revenue decline.
-   Recurring single-use products represent roughly 85% of revenue, underpinning stable demand and contributing to gross margin improvement.
-   Gross margin expanded by approximately 260 basis points due to a favorable product mix, foreign-exchange effects and benefits from terminating a distribution arrangement; supply‑chain optimization efforts are ongoing.

Original SEC Filing: CONMED Corp \[ CNMD \] - 10-Q - Apr. 30, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CNMD.US](https://longbridge.com/en/quote/CNMD.US.md)

## Related News & Research

- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [FRONTERA ANNOUNCES FIRST QUARTER 2026 RESULTS | FECCF Stock News](https://longbridge.com/en/news/286507909.md)
- [Elkem updates financial calendar for 2026 reporting schedule](https://longbridge.com/en/news/286917298.md)
- [Wide postpones 2026 annual meeting to June 17; proxy voting deadline June 16](https://longbridge.com/en/news/286911986.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)